Date 28 May 2014
Documents : 4
History
(Restricted access link)

KLIOGEST - NOVEFEMME - TRISEQUENS

Opinions on drugs - Posted on Jul 16 2014

Reason for request

Reassessment of the Actual Benefit of all medicines indicated in hormone replacement therapy for menopause at the request of the Committee, pursuant to Article R-163-21 of the French Social Security Code

Clinical Benefit

Substantial

The actual benefit of the proprietary medicinal products KLIOGEST, NOVOFEMME and TRISEQUENS in hormone replacement therapy (HRT) for symptoms of oestrogen deficiency in menopausal women remains substantial in patients for whom climacteric disorders are described as troublesome enough to impair their quality of life when these proprietary medicinal products are used as per the Committee's recommendations.

Therapeutic use